
Opinion|Videos|August 5, 2024
Improving RSV Vaccination Rates and Addressing Misinformation
Experts on RSV provide insights on improving RSV vaccination rates, highlighting ways to navigate misinformation.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How do you avoid any missed chances to vaccinate against RSV?
- How do you address misinformation out there about RSV with patients?
Advertisement
Related to this article

Report urges payment reform, food policy changes, and wider treatment access, warning that drugs alone can't fix obesity's root causes.

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

A TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.

β3 agonists were not linked to lower dementia incidence vs anticholinergics among 830,393 adults treated for overactive bladder, a cohort study found.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
4
Nondrug Therapies Ease Cough in Lung Cancer, Pulmonary Rehab Leads Pack
5


